L. Ny

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy

H. Helgadottir, S. Rotstein, M. Bergqvist, 2022, Acta oncologica.

Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.

I. Johansson, R. Olofsson Bagge, J. Dwarkasing, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor

G. Brunlöf, S. Wallerstedt, Carina Tukukino, 2007, European Journal of Clinical Pharmacology.

Risk of clinically relevant bleeding in warfarin‐treated patients—influence of SSRI treatment

A. Sundström, S. Wallerstedt, L. Stigendal, 2009, Pharmacoepidemiology and drug safety.

BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis

J. Geisler, J. Koivunen, L. Oddershede, 2020, Acta oncologica.

Bacterial flora of the human oral cavity, and the upper and lower esophagus.

M. Ruth, L. Ny, G. Dahlén, 2013, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

A. Carneiro, A. Arance, G. Long, 2021, Journal of Clinical Oncology.